title: Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.
abstract: The immune response to recombinant adenoviruses is the most significant impediment to their clinical use for immunization. We test the hypothesis that specific virus-antibody combinations dictate the type of immune response generated against the adenovirus and its transgene cassette under certain physiological conditions while minimizing vector-induced toxicity. In vitro and in vivo assays were used to characterize the transduction efficiency, the T and B cell responses to the encoded transgene, and the toxicity of 1 × 10(11) adenovirus particles mixed with different concentrations of neutralizing antibodies. Complexes formed at concentrations of 500 to 0.05 times the 50% neutralizing dose (ND(50)) elicited strong virus- and transgene-specific T cell responses. The 0.05-ND(50) formulation elicited measurable anti-transgene antibodies that were similar to those of virus alone (P = 0.07). This preparation also elicited very strong transgene-specific memory T cell responses (28.6 ± 5.2% proliferation versus 7.7 ± 1.4% for virus alone). Preexisting immunity significantly reduced all responses elicited by these formulations. Although lower concentrations (0.005 and 0.0005 ND(50)) of antibody did not improve cellular and humoral responses in naïve animals, they did promote strong cellular (0.005 ND(50)) and humoral (0.0005 ND(50)) responses in mice with preexisting immunity. Some virus-antibody complexes may improve the potency of adenovirus-based vaccines in naïve individuals, while others can sway the immune response in those with preexisting immunity. Additional studies with these and other virus-antibody ratios may be useful to predict and model the type of immune responses generated against a transgene in those with different levels of exposure to adenovirus.
authors.affiliation: Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas, USA.
authors.forename: Jin Huk
authors.initials: JH
authors.lastname: Choi
authors.forename: Joe
authors.initials: J
authors.lastname: Dekker
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Schafer
authors.forename: Jobby
authors.initials: J
authors.lastname: John
authors.forename: Craig E
authors.initials: CE
authors.lastname: Whitfill
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Petty
authors.forename: Eid E
authors.initials: EE
authors.lastname: Haddad
authors.forename: Maria A
authors.initials: MA
authors.lastname: Croyle
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000906:Antibodies / Q000097:blood; D000914:Antibodies, Viral / Q000276:immunology*; D000936:Antigen-Antibody Complex / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D005822:Genetic Vectors; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013601:T-Lymphocytes / Q000276:immunology; D014161:Transduction, Genetic; D014612:Vaccines / Q000276:immunology*
chemical_list: D000906:Antibodies; D000914:Antibodies, Viral; D000936:Antigen-Antibody Complex; D014612:Vaccines
references.citation: Virology. 1973 Apr;52(2):456-67
references.pmid: 4705382
references.citation: Mol Ther. 2009 Aug;17(8):1333-9
references.pmid: 19513019
references.citation: Arch Immunol Ther Exp (Warsz). 2009 Sep-Oct;57(5):311-23
references.pmid: 19688186
references.citation: Expert Rev Vaccines. 2007 Apr;6(2):255-66
references.pmid: 17408374
references.citation: Mol Ther. 2007 Aug;15(8):1410-6
references.pmid: 17505469
references.citation: J Gene Med. 2006 May;8(5):566-76
references.pmid: 16508909
references.citation: Hum Gene Ther. 2002 Oct 10;13(15):1887-900
references.pmid: 12396620
references.citation: Mol Ther. 2008 Jan;16(1):16-29
references.pmid: 17912234
references.citation: Expert Opin Biol Ther. 2009 Oct;9(10):1279-87
references.pmid: 19645630
references.citation: J Virol. 2007 Dec;81(24):13801-8
references.pmid: 17942539
references.citation: Biol Pharm Bull. 2008 Oct;31(10):1819-25
references.pmid: 18827334
references.citation: J Cell Biochem. 2009 Nov 1;108(4):778-90
references.pmid: 19711370
references.citation: Hum Gene Ther. 2010 Jul;21(7):891-901
references.pmid: 20180652
references.citation: Expert Rev Vaccines. 2009 Jun;8(6):761-77
references.pmid: 19485756
references.citation: J Virol. 2011 May;85(9):4222-33
references.pmid: 21325402
references.citation: Gene Ther. 2008 Dec;15(24):1606-17
references.pmid: 18615115
references.citation: Immunity. 2010 Oct 29;33(4):504-15
references.pmid: 21029961
references.citation: Curr Gene Ther. 2009 Apr;9(2):115-27
references.pmid: 19355869
references.citation: Parasite Immunol. 2009 Sep;31(9):529-38
references.pmid: 19691552
references.citation: Gene Ther. 1996 Feb;3(2):137-44
references.pmid: 8867861
references.citation: J Pharmacol Toxicol Methods. 2008 Nov-Dec;58(3):222-32
references.pmid: 18723098
references.citation: J Virol. 2005 Jun;79(12):7478-91
references.pmid: 15919903
references.citation: Curr Gene Ther. 2007 Aug;7(4):272-83
references.pmid: 17969560
references.citation: Expert Rev Vaccines. 2007 Jun;6(3):347-56
references.pmid: 17542750
references.citation: J Exp Med. 2008 Nov 24;205(12):2717-25
references.pmid: 18981239
references.citation: Methods. 1997 Jun;12(2):117-23
references.pmid: 9184376
references.citation: J Biomed Mater Res. 1994 Jan;28(1):81-90
references.pmid: 8126033
references.citation: Mol Genet Metab. 2003 Sep-Oct;80(1-2):148-58
references.pmid: 14567964
references.citation: J Virol. 1997 Nov;71(11):8798-807
references.pmid: 9343240
references.citation: Virus Res. 2008 Mar;132(1-2):1-14
references.pmid: 18036698
references.citation: Pharm Dev Technol. 1998 Aug;3(3):373-83
references.pmid: 9742558
references.citation: Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19940-5
references.pmid: 19918060
references.citation: J Immunol. 1995 Sep 1;155(5):2564-70
references.pmid: 7650386
references.citation: Methods Mol Med. 2007;130:223-35
references.pmid: 17401177
references.citation: J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S41-52
references.pmid: 20176268
references.citation: Gene Ther. 1999 Sep;6(9):1574-83
references.pmid: 10490767
references.citation: J Med Virol. 2010 Mar;82(3):407-14
references.pmid: 20087930
references.citation: Curr Drug Targets. 2009 Feb;10(2):158-75
references.pmid: 19199912
references.citation: J Virol. 2010 Jan;84(1):630-8
references.pmid: 19846512
references.citation: J Virol Methods. 2008 Mar;148(1-2):132-45
references.pmid: 18160141
references.citation: Curr Gene Ther. 2007 Aug;7(4):229-38
references.pmid: 17969556
references.citation: J Immunol. 2008 Aug 1;181(3):2134-44
references.pmid: 18641352
references.citation: Expert Opin Biol Ther. 2009 Dec;9(12):1521-31
references.pmid: 19780714
references.citation: J Virol. 2007 Apr;81(7):3170-80
references.pmid: 17229689
references.citation: Adv Exp Med Biol. 2011;780:113-24
references.pmid: 21842369
references.citation: J Virol. 2001 May;75(10):4792-801
references.pmid: 11312351
references.citation: Nat Med. 2009 Aug;15(8):873-5
references.pmid: 19620961
references.citation: J Immunol. 2005 Jun 1;174(11):7179-85
references.pmid: 15905562
references.citation: Mol Ther. 2006 Jan;13(1):108-17
references.pmid: 16198149
references.citation: J Virol. 2008 Dec;82(23):11705-13
references.pmid: 18815305
references.citation: J Virol. 2006 Oct;80(20):10237-47
references.pmid: 17005701
references.citation: J Virol. 2009 Jan;83(1):479-83
references.pmid: 18945780
references.citation: Nature. 2008 Mar 6;452(7183):103-7
references.pmid: 18288107
references.citation: J Virol. 1998 Apr;72(4):2945-54
references.pmid: 9525615
references.citation: J Virol. 2009 Jun;83(11):5567-73
references.pmid: 19279092
references.citation: Curr Gene Ther. 2007 Oct;7(5):297-305
references.pmid: 17979676
references.citation: Cell Biol Toxicol. 2003 Jun;19(3):145-59
references.pmid: 12945743
references.citation: J Clin Microbiol. 2006 Oct;44(10):3781-3
references.pmid: 17021110